## APPENDIX A

## **CLEAN COPY OF CLAIMS AS AMENDED HEREIN**

1. A method of treating or preventing atherosclerosis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the Formula I:

## Formula I

wherein:

A is a covalent bond;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

R<sup>5</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl.

3. The method of claim 1, wherein  $\mathbb{R}^4$  is optionally substituted alkyl.

- 4. The method of claim 3, wherein R<sup>3</sup> is optionally substituted aryl or optionally substituted heteroaryl.
  - 7. The method of claim 4, wherein  $R^3$  is optionally substituted phenyl.
  - 8. The method of claim 7, wherein R<sup>4</sup> is alkyl of 1-8 carbon atoms.
- 9. The method of claim 8, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is methyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-methylthio-1,3,5-triazine-2-ylamine.
- 10. The method of claim 8, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is n-pentyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.
- 12. The method of claim 8, wherein R<sup>3</sup> is 3-chlorophenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely 4-[(3-chlorophenylamino)methyl]-6-methylthio-[1,3,5]triazin-2-ylamine.
- 13. The method of claim 8, wherein  $R^3$  is 2,4-dimethoxyphenyl,  $R^4$  is methyl, and  $R^5$  is hydrogen, namely N-{[(3,5-dimethoxyphenyl]aminomethyl}-4-methylthio-1,3,5-triazine-2-ylamine;
- 34. The method of claim 1, further comprising coadministration of a therapeutically effective amount of a compound that lowers LDL cholesterol.
- 35. The method of claim 34, wherein the LDL cholesterol lowering compound is chosen from clofibrate, gemfibrozil, and fenofibrate, nicotinic acid, mevinolin, mevastatin, pravastatin, simvastatin, fluvastatin, lovastatin, cholestyrine, colestipol and probucol.

## 36. A compound of the Formula I:

Formula I

wherein:

A is a covalent bond;

R<sup>1</sup> and R<sup>2</sup> are hydrogen;

R<sup>3</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;

R<sup>4</sup> is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; and

R<sup>5</sup> is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl

with the proviso that when  $R^4$  is methyl or ethyl,  $R^3$  cannot be lower alkyl or unsubstituted phenyl.

- 39. The compound of claim 36, wherein R<sup>3</sup> is optionally substituted aryl or optionally substituted heteroaryl.
  - 42. The compound of claim 39, wherein R<sup>3</sup> is optionally substituted phenyl.
  - 43. The compound of claim 42, wherein R<sup>4</sup> is alkyl of 1-8 carbon atoms.

- 44. The compound of claim 43, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is methyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.
- 45. The compound of claim 43, wherein R<sup>3</sup> is 4-t-butylphenyl and R<sup>4</sup> is n-pentyl, namely 6-{[4-(tert-butyl)phenoxy]methyl}-4-pentylthio-1,3,5-triazine-2-ylamine.
- 46. The compound of claim 43, wherein R<sup>3</sup> is 3-chlorophenyl, R<sup>4</sup> is methyl, and R<sup>5</sup> is hydrogen, namely 4-[(3-chlorophenylamino)methyl]-6-methylthio-[1,3,5]triazin-2-ylamine.
- 47. The compound of claim 43, wherein  $R^3$  is 2,4-dimethoxyphenyl,  $R^4$  is methyl, and  $R^5$  is hydrogen, namely N-{[(3,5-dimethoxyphenyl]aminomethyl}-4-methylthio-1,3,5-triazine-2-ylamine.
- 63.A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 36.